Royalty Pharma plc

NasdaqGS:RPRX

Sector

🏥 Health Care

Industries

🧬 Biotechnology

💰 Investment Banking & Asset Management

💊 Pharmaceuticals

💼 Private Equity

💰 Venture Capital

Location

United States

Market Cap

USD 21.20 B

Share Price

USD 36.35

Avg Daily Volume

4,258,177

Change (1 day)

-0.41%

Change (1 year)

32.62%

Change (YTD)

42.49%

Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending June 30, 2025: 82.10%

Royalty Pharma plc EBITDA Margin is 82.10% for the Trailing 12 Months (TTM) ending June 30, 2025, a 27.40% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending June 30, 2024 was 64.44%, a 147.16% change year over year.
Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending June 30, 2023 was 26.07%, a -49.05% change year over year.
Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending June 30, 2022 was 51.17%, a -39.57% change year over year.
Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending June 30, 2021 was 84.67%, a -38.41% change year over year.